[
  {
    "question": "Progressive Proximal weakness case, with AR pattern, brother and sister has it, ck high, emg: MUAP. dx?",
    "option_a": "SMA",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "This case describes a patient with progressive proximal muscle weakness, an autosomal recessive pattern of inheritance (affecting both brother and sister), high creatine kinase levels, and electromyographic findings of altered motor unit action potentials\u2014features that are typical for a myopathic process rather than a neurogenic one. Limb girdle muscular dystrophy (LGMD) is a group of inherited myopathies that usually presents with these clinical findings. LGMD results from various gene mutations (such as those affecting sarcoglycan complex, dysferlin, or calpain-3) that disrupt normal muscle fiber structure and function. The mutated proteins lead to muscle fiber degeneration and replacement by fat and connective tissue. The autosomal recessive forms typically show a similar pattern of involvement in siblings. EMG in LGMD demonstrates myopathic motor unit action potentials (short duration, low amplitude, polyphasic), and serum CK is usually markedly elevated due to muscle breakdown. Clinically, patients present with proximal muscle weakness, difficulty climbing stairs, rising from chairs, or lifting objects. The pattern of inheritance and involvement of multiple family members (both genders) strongly support an autosomal recessive muscular dystrophy rather than a motor neuron disease like SMA, which exhibits a different electrophysiologic profile and typically normal or only slightly elevated CK. Evaluation includes: serum CK measurement (often high in myopathies), EMG (which shows myopathic changes), muscle biopsy, and confirmatory genetic testing. Differential diagnoses include spinal muscular atrophy (SMA) \u2013 which would show a neurogenic pattern on EMG and typically normal CK levels \u2013 and inflammatory myopathies. Muscle biopsy and genetic analyses help differentiate these conditions. There is currently no cure for LGMD; management is supportive. First-line management includes physical therapy, occupational therapy, and exercise programs to maintain mobility and prevent contractures. Orthopedic interventions, assistive devices, and sometimes respiratory support are considered in advanced stages. Genetic counseling is essential. Although there is no standard pharmacotherapy, clinical trials are evaluating gene therapy and targeted molecular treatments. In pregnancy and lactation, supportive management continues with multidisciplinary care and careful monitoring to maintain function. Option A (SMA) is incorrect because SMA is a motor neuron disease with neurogenic EMG findings and usually only mildly elevated or normal CK. The marked answer, Option B (assumed here to represent LGMD), is the correct diagnosis given the clinical and laboratory findings. Options C and D are not provided, thereby reinforcing the focus on differentiating LGMD from SMA. 1. Markedly high CK levels combined with a myopathic pattern on EMG in a patient with proximal weakness and a positive family history strongly indicate a muscular dystrophy rather than a neurogenic disorder. 2. Autosomal recessive inheritance implies both sexes are equally affected, which supports LGMD over conditions like SMA that might show different inheritance patterns. Recent research continues to explore the molecular basis of various LGMD subtypes with trials evaluating gene and molecular therapies. Although no disease\u2010modifying treatments currently exist, early diagnosis and supportive management are emphasized in current neuromuscular guidelines.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Case of a post bariatric surgery patient came with a picture of vit b12 deficiency however its level is normal, what to give?",
    "option_a": "Folate",
    "option_b": "Copper",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "Post\u2013bariatric surgery patients are at risk for multiple nutritional deficiencies. Although vitamin B12 deficiency is a common concern, similar neurological manifestations (such as subacute combined degeneration or peripheral neuropathy) may occur due to copper deficiency. Copper is essential for the function of many enzymes involved in the maintenance of neural and hematologic function. Malabsorption after bariatric surgery can lead to copper deficiency, which in turn can result in demyelination in the dorsal columns and lateral corticospinal tracts, thereby mimicking a vitamin B12 deficiency syndrome. The patient presents with neurological symptoms resembling B12 deficiency (e.g., neuropathy or myelopathy), yet actual serum levels of B12 are normal. In such cases, the clinical picture should prompt evaluation for alternative nutritional deficits, with copper deficiency being a well-documented culprit in post\u2013bariatric surgery patients. Diagnostic evaluation should include measurement of serum copper levels and ceruloplasmin, in addition to a thorough nutritional panel. Differentials include true vitamin B12 deficiency, folate deficiency (which does not usually cause neurological manifestations of this severity), and less common metabolic disorders. A detailed dietary history and review of bariatric surgery complications assist in diagnosis. The first-line management is copper supplementation, delivered orally or intravenously based on the severity of the deficiency. Regular monitoring of copper levels is recommended to avoid toxicity. In pregnancy and lactation, copper supplementation is considered safe and necessary when deficiency is documented, but dosing should be carefully monitored under specialist guidance. Long-term follow-up is needed to manage and prevent recurrence. Option A (Folate) is not appropriate as folate deficiency does not typically produce a neurological syndrome that mimics B12 deficiency. Option B (Copper) is correct because copper deficiency can produce subacute myelopathy and neuropathy similar to B12 deficiency and is a recognized post\u2013bariatric surgery complication. Options C and D are not provided. 1. Always consider copper deficiency as a cause of a B12 deficiency\u2013like neurological syndrome in patients with a history of bariatric surgery, even when vitamin B12 levels are normal. 2. Copper plays a crucial role in myelin formation and neural function; deficiency can lead to significant neurologic dysfunction. Recent studies underline the need for routine monitoring of trace elements, including copper, in patients post\u2013bariatric surgery. Guidelines recommend a multidisciplinary approach to nutritional supplementation in these patients, and emerging research is focused on optimal dosing regimens to prevent neurologic complications.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Case of limb girdle a2? about what to do? (Not sure) (2A usually spare Cardiac)",
    "option_a": "Echo",
    "option_b": "Pulmonary function test",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "Limb girdle muscular dystrophy (LGMD) type 2A, also known as calpainopathy, is an autosomal recessive disorder characterized by progressive proximal muscle weakness. A notable feature mentioned is that cardiac involvement is usually minimal or spared in LGMD 2A, which directs clinical focus toward other systems such as respiratory function. LGMD 2A is due to mutations in the calpain-3 gene, leading to defective proteolysis within muscle fibers, muscle degeneration, and replacement with connective tissue. Unlike some other muscular dystrophies, LGMD 2A typically spares the cardiac muscle; however, respiratory muscles can eventually be affected, warranting periodic evaluation. Patients usually present with gradual weakness of the pelvic and shoulder girdle muscles. Although significant cardiomyopathy is uncommon in LGMD 2A, a decline in respiratory muscle strength may contribute to reduced pulmonary function, especially in later stages of the disease. The diagnosis is established through a combination of clinical assessment, serum CK levels, EMG studies (which reveal myopathic changes), muscle biopsy, and confirmatory genetic testing. Differential diagnoses include other forms of LGMD and inflammatory myopathies. Since cardiac involvement is rare in LGMD 2A, clinicians prioritize evaluating respiratory status using pulmonary function tests (PFTs). Management is primarily supportive. First-line interventions include regular physical therapy, exercise programs tailored to preserve function, and orthopedic management of complications. Routine pulmonary function tests are recommended to monitor respiratory muscle strength. Should respiratory compromise occur, interventions such as non-invasive ventilation may be indicated. Given the minimal cardiac involvement in LGMD 2A, routine echocardiography is less prioritized. In pregnancy and lactation, care continues with multidisciplinary support, and respiratory function should be monitored closely to ensure maternal and fetal well-being. Option A (Echocardiography) might be considered in many muscular dystrophies; however, in LGMD 2A cardiac involvement is generally spared, making routine PFTs (Option B) more relevant. Hence, Option B\u2014Pulmonary Function Test\u2014is the correct choice for monitoring disease progression and respiratory status in these patients. 1. LGMD 2A typically spares the heart, which shifts the focus to monitoring respiratory muscle involvement using pulmonary function tests. 2. Regular evaluation of pulmonary function is crucial even in neuromuscular disorders where cardiac involvement is minimal, as respiratory failure can be a late but significant complication. Recent neuromuscular guidelines emphasize periodic respiratory evaluations in all muscular dystrophies, including LGMD 2A. Studies continue to support the use of non-invasive PFTs for early detection of respiratory decline, and ongoing research is assessing potential therapeutic interventions aimed at preserving respiratory function.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Case with (features of POEM) LL edema, neuropathy?",
    "option_a": "VEGF",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "POEMS syndrome is a rare multisystem paraneoplastic disorder characterized by the constellation of features: Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein, and Skin changes. One of the hallmark laboratory findings in POEMS is an elevated vascular endothelial growth factor (VEGF) level. The pathogenesis of POEMS syndrome is not entirely understood, but overproduction of VEGF by the abnormal plasma cell clone leads to increased vascular permeability, angiogenesis, and subsequent end-organ manifestations such as edema and neuropathy. This VEGF elevation is central to the syndrome\u2019s clinical manifestations. Patients often present with a sensorimotor polyneuropathy accompanied by lower limb edema, organomegaly (like hepatosplenomegaly), endocrinopathies, and characteristic skin changes. The elevated VEGF level is a key diagnostic clue that helps differentiate POEMS syndrome from other causes of neuropathy such as chronic inflammatory demyelinating polyneuropathy (CIDP) or diabetic neuropathy. Diagnosis involves a combination of clinical findings, electrophysiological studies, laboratory assessments (including serum and plasma VEGF levels), and the detection of a monoclonal protein (typically lambda-chain restricted). The differential diagnosis may include CIDP, amyloidosis, and other paraneoplastic syndromes, but the markedly elevated VEGF level in POEMS is a distinguishing feature. The mainstay of treatment is targeting the underlying plasma cell dyscrasia. For localized disease, radiotherapy may be used, while systemic therapy with agents such as lenalidomide, thalidomide, or melphalan combined with dexamethasone is used for more disseminated disease. High-dose chemotherapy with autologous stem cell transplantation may be considered in eligible patients. In pregnancy and lactation, treatment choices must be carefully weighed; for example, radiotherapy is generally contraindicated and chemotherapeutic options require risk\u2013benefit analysis with a multidisciplinary team. Option A, VEGF, is correct as the elevated VEGF level is a critical biomarker in the diagnosis and monitoring of POEMS syndrome. Its measurement helps differentiate POEMS from other neuropathies. Other options are either not provided or do not align with the key diagnostic marker for this syndrome. 1. A markedly elevated VEGF level is highly supportive of a POEMS syndrome diagnosis, especially when accompanied by neuropathy and systemic features. 2. The acronym POEMS reminds clinicians of the multisystem involvement \u2013 always consider screening for monoclonal protein and organ involvement when the clinical picture is complex. Recent clinical guidelines and studies continue to validate serum VEGF as a reliable biomarker for diagnosing and tracking treatment response in POEMS syndrome. Emerging treatments targeting the plasma cell clone and modulating VEGF levels are under investigation, offering hope for more effective management strategies.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Which muscle supplied by 12th cranial nerve?",
    "option_a": "hypoglossus",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "The 12th cranial nerve, known as the hypoglossal nerve, is a pure motor nerve responsible for innervating nearly all the intrinsic and extrinsic muscles of the tongue. These include the genioglossus, hyoglossus, and styloglossus muscles. The option given (hypoglossus) is intended to denote a tongue muscle innervated by CN XII. Injury or lesions of the hypoglossal nerve lead to impaired tongue mobility. Denervation causes atrophy over time and manifests clinically as tongue deviation towards the affected side on protrusion, along with dysarthria. Current neuroimaging and electrophysiological studies help document the site and extent of the lesion. Patients with hypoglossal nerve deficits typically present with difficulties in speech and swallowing. On examination, the tongue deviates toward the side of the lesion when protruded, which is a key clinical sign. This directly correlates with the motor function provided by this nerve. The evaluation includes a detailed cranial nerve examination, with special attention to tongue movements. Further studies might include MRI of the brainstem and neck, and if a lesion is suspected, nerve conduction studies or electromyography (EMG) may be useful to assess the integrity and conduction of the nerve. Management of hypoglossal nerve deficits involves identifying and treating the underlying cause. For many conditions, conservative management with speech and swallowing therapy is initially recommended. In cases with compressive lesions, surgical decompression or resection of the mass may be necessary. In pregnant or lactating patients, imaging studies and interventions are chosen carefully to avoid fetal or infant exposure to ionizing radiation or teratogenic agents; ultrasound or MRI without contrast are preferable, and medications should be selected based on their pregnancy category. Option A refers to a tongue muscle supplied by the hypoglossal nerve. Although the term 'hypoglossus' might be misinterpreted as relating directly to the nerve name, in the context of the question it is recognized as referring to one of the tongue muscles innervated by CN XII. With the other options not provided, Option A remains the only correct choice. \u2022 The hypoglossal nerve innervates all intrinsic and extrinsic tongue muscles except the palatoglossus (innervated by the vagus nerve).\n\u2022 Tongue deviation on protrusion is a classic sign of hypoglossal nerve dysfunction.\n\u2022 Early identification of a hypoglossal lesion can lead to better outcomes through targeted rehabilitation. Recent studies emphasize early neuroimaging and electrophysiological assessment in patients with cranial nerve deficits. Guidelines continue to recommend conservative management with rehabilitation as a first-line treatment, with surgical intervention reserved for cases where a structural lesion is impinging on the nerve.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Young lady slip vaginal delivery presented with right thigh numbness and heaviness. On exam she has weak hip flexion and knee extension, and \u2193 pinprick sensation in anteromedial right thigh. Which lower limb nerve is likely affected?",
    "option_a": "obturator nerve",
    "option_b": "pudendal nerve",
    "option_c": "femoral nerve",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuromuscular",
    "explanation": "The femoral nerve originates from the lumbar plexus (L2-L4) and is crucial for motor innervation of the quadriceps (responsible for knee extension) and contributes to hip flexion (via the iliopsoas, although primarily innervated by direct branches from L1-L3). It also provides sensory innervation to the anteromedial thigh and, via its saphenous branch, the medial leg and foot. During vaginal delivery, particularly with challenging positions or prolonged labor, the femoral nerve can be stretched or compressed, leading to neuropraxia or axonal injury. This results in a decrease in motor function (weak hip flexion and knee extension) and impaired sensory perception in its distribution area. The clinical presentation of weak knee extension (quadriceps weakness) and diminished hip flexion, along with decreased pinprick sensation in the anteromedial thigh, closely mirrors the anatomic distribution of the femoral nerve. Patients might report a sensation of heaviness or numbness that affects mobility. Diagnosis is primarily clinical, based on a focused neurological exam. Differential diagnoses include an obturator nerve injury (which would impair hip adduction rather than knee extension) and lumbosacral radiculopathy (which often has a broader distribution of symptoms). Electrophysiological studies (e.g., nerve conduction studies and EMG) may be employed if the diagnosis is uncertain. Initial management is generally conservative, including physical therapy to maintain muscle strength and prevent contractures. Pain management and observation for nerve recovery are standard. In cases with severe deficits, further investigations such as MRI or nerve conduction studies may be warranted. For postpartum patients, medications and therapeutic interventions should be chosen with consideration for breastfeeding; non-steroidal anti-inflammatories and physical therapy are usually safe. Option C (femoral nerve) correctly aligns with the clinical findings of weakness in hip flexion and knee extension while affecting the anteromedial thigh sensation. Option A (obturator nerve) primarily affects hip adduction, whereas Option B (pudendal nerve) is more related to perineal sensation and function. Thus, Option C is the best answer. \u2022 The femoral nerve is integral for both motor functions (hip flexion and knee extension) and sensory distribution to the anteromedial thigh and medial leg.\n\u2022 Stretch or compressive injuries to the femoral nerve can occur during labor, especially with prolonged or awkward positioning.\n\u2022 Early recognition and physical therapy can greatly improve functional recovery. Current guidelines stress the importance of early clinical recognition of postpartum nerve injuries. Conservative management with rehabilitation is favored, and recent research supports the use of early physiotherapy to accelerate functional recovery in femoral nerve injuries.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Young lady slip vaginal hysterectomy come with upper thigh numbness. She has significantly weak hip adductors, slight weak hip flexion. No other issues. Which nerve affected?",
    "option_a": "obturator",
    "option_b": "femoral",
    "option_c": "sciatic",
    "option_d": "lumbosacral plexus",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "The obturator nerve originates from the lumbar plexus (L2-L4) and primarily innervates the adductor muscles of the thigh. It also provides cutaneous sensory innervation to the medial aspect of the thigh. The marked weakness in hip adductors is a cardinal sign of obturator nerve injury. Obturator nerve injuries can occur during pelvic surgeries (such as hysterectomy) due to inadvertent transection, traction, or compression. The resultant neuropathy leads to significant weakness of the hip adductors and sensory deficits in the medial thigh. The patient\u2019s presentation with significant weakness in hip adduction, combined with upper thigh numbness, points directly to an injury of the obturator nerve. The slight weakness in hip flexion might be explained by partial overlap with other nerve contributions, but the predominant deficit remains adduction. Diagnosis is established by correlating the clinical exam with the typical adductor weakness and medial thigh sensory loss. Differential diagnoses include femoral nerve injury (which would affect knee extension and anterior thigh sensation) and lumbosacral plexus injury (which would present with a broader pattern of deficits). Electrophysiological studies can help confirm obturator nerve involvement if needed. Management includes physical therapy to strengthen remaining musculature and prevent compensatory injuries. In cases of severe injury, surgical intervention may be considered for nerve repair. During pregnancy-related surgeries and in lactating women, extra caution is exercised to minimize nerve injury with the use of nerve monitoring, and post-operatively, medications and therapies are selected based on their safety profiles in these populations. Option A (obturator) is the correct choice based on the clinical findings of significant hip adductor weakness and medial thigh sensory deficits. Option B (femoral) would typically result in deficits related to knee extension and anterior thigh sensation, while Option C (sciatic) would produce a broader motor and sensory loss affecting the posterior compartment of the thigh and leg. Option D (lumbosacral plexus) would have a wider array of deficits. \u2022 The obturator nerve is particularly vulnerable during pelvic surgeries, notably hysterectomy.\n\u2022 Its primary role is in hip adduction, making weakness in these muscles a key indicator of injury.\n\u2022 Early intervention and rehabilitation can help mitigate long-term functional loss. Recent surgical guidelines and studies have focused on protective techniques during pelvic surgeries to minimize obturator nerve injury. Advances in intraoperative nerve monitoring have further improved outcomes, and current postoperative management emphasizes early physical therapy as supported by the latest clinical research.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "What is the most common deficit occur post elbow joint trauma?",
    "option_a": "wrist drop",
    "option_b": "claw hand",
    "option_c": "cheralgia paresthetica",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "Elbow joint trauma can lead to nerve injuries due to the close proximity of several nerves around the elbow. The ulnar nerve, which courses posterior to the medial epicondyle in the cubital tunnel, is particularly vulnerable. Injury to the ulnar nerve typically presents with a 'claw hand' due to weakness of the intrinsic hand muscles. Following elbow trauma, the ulnar nerve may be subjected to compression, traction, or contusion. Such injuries lead to demyelination or, in severe cases, axonal loss. The resultant motor deficit, characterized by the inability to properly control finger movements (leading to clawing), results from paralysis of the intrinsic hand muscles that the ulnar nerve supplies. Patients with ulnar nerve injuries often exhibit a claw hand deformity, which is most evident on attempting to extend the fingers. Sensory loss along the medial aspect of the hand and forearm is also common. This pattern of deficits is much more typical in ulnar nerve injury than in radial nerve injury (which would result in wrist drop) when related to elbow trauma. Diagnosis is based on a thorough clinical examination focusing on motor and sensory function of the hand. Nerve conduction studies and electromyography (EMG) help assess the severity and type of nerve involvement. Differential diagnoses include radial nerve injury (wrist drop) and median nerve injury (affecting thumb opposition and other hand functions). Initial treatment is typically conservative, involving splinting to prevent deformity and physical therapy to maintain muscle strength and joint mobility. If there is no improvement, surgical decompression or nerve transposition may be considered. In pregnant and lactating patients, conservative management is often preferred, and if surgery is necessary, it is deferred until after delivery or performed with careful risk-benefit analysis using techniques that minimize fetal and neonatal risks. Option B, indicating claw hand, is the correct answer as it directly corresponds to the deficit seen with ulnar nerve injury at the elbow. Option A (wrist drop) is associated with radial nerve injury, which is more common in humeral shaft fractures rather than direct elbow trauma. Option C (cheralgia paresthetica) is unrelated to elbow injuries, as it refers to a sensory neuropathy of the lateral thigh. \u2022 The ulnar nerve is especially vulnerable at the elbow due to its superficial course at the cubital tunnel.\n\u2022 Claw hand is a hallmark sign of ulnar nerve injury and reflects the loss of intrinsic hand muscle function.\n\u2022 Early recognition and rehabilitation are key to preventing long-term functional deficits. Recent clinical studies underscore the importance of early electrodiagnostic evaluation in cases of suspected ulnar nerve injury post-elbow trauma. Updated guidelines favor initial conservative management with physical therapy and recommend surgical intervention only if there is evidence of significant nerve compression or if conservative treatment fails.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "63 years old male, has acute bilateral lower limbs weakness, lower back pain, urinary incontinence. Exam shows dense paraplegia, and L empick sensation up to midthoracic area, preserved proprioception. DX?",
    "option_a": "Spinal cord infarction",
    "option_b": "Transverse myelitis",
    "option_c": "GBS",
    "option_d": "Syringo myelia",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "This case describes an acute spinal cord syndrome characterized by sudden bilateral lower limb weakness, back pain, urinary incontinence, and a sensory level with preserved proprioception. In anterior spinal artery syndrome, typically caused by spinal cord infarction, motor function and pain/temperature are affected while the dorsal columns (proprioception and vibration) are spared. Spinal cord infarction usually results from occlusion of the anterior spinal artery, which supplies the anterior two\u2010thirds of the cord. This leads to ischemia of the corticospinal tracts (resulting in paraplegia) and the spinothalamic tracts (resulting in loss of pain and temperature sensation), while the dorsal columns are preserved. Risk factors include atherosclerosis, embolic events, or complications from aortic surgery in some cases. The patient\u2019s acute presentation with lower back pain, rapid onset bilateral paraplegia, a distinct sensory level (up to midthoracic), and preserved dorsal column function is classic for anterior spinal artery syndrome due to spinal cord infarction. The presence of urinary incontinence further supports involvement of the autonomic pathways in the anterior portion of the cord. The differentials include: (1) Transverse myelitis (subacute onset, more inflammatory, often with involvement of all cord tracts), (2) Guillain\u2013Barr\u00e9 Syndrome (peripheral nerve disorder lacking a defined sensory level and usually ascending weakness without sphincter involvement), and (3) Syringomyelia (typically chronic with a \"cape\u2010like\" distribution affecting the upper limbs). MRI with diffusion-weighted imaging and vascular studies are used to confirm infarction. Management remains largely supportive. First-line treatment focuses on stabilization of hemodynamics and supportive care. There is no proven role for thrombolytic therapy in spinal cord infarction at present. Secondary prevention includes risk factor modification and antiplatelet agents. In pregnant or lactating patients, management remains supportive while considering the safety profile of medications (most antiplatelet drugs are classified as relatively safe in lactation and pregnancy should prompt a careful risk\u2013benefit analysis). Rehabilitation plays a key role in recovery. Option A (Spinal cord infarction) is correct given the acute onset with a sensory level and preserved proprioception. Option B (Transverse myelitis) usually presents in a subacute manner and may not spare dorsal columns. Option C (GBS) is a peripheral neuropathy and would not present with a clear sensory level or bladder involvement typical of a central lesion. Option D (Syringomyelia) is typically a chronic process causing a cape-like distribution of sensory loss, not an acute paraplegia. \u2022 Preservation of dorsal column sensation in the setting of acute paraplegia strongly suggests an anterior cord syndrome. \u2022 Acute back pain preceding neurological deficits is a red flag for vascular causes of myelopathy. Recent studies emphasize early diagnosis via MRI, though there is no specific acute intervention proven to reverse spinal cord infarction. Ongoing research focuses on neuroprotective agents and improved rehabilitation strategies, with current guidelines continuing to recommend supportive management and secondary prevention.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Patient with upper limbs numbness and \u2193 pinprick sensation around deltoid area in a cape like distribution, preserved position and vibration. Diagnosis?",
    "option_a": "syringomyelia",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "This clinical vignette characterizes a patient with sensory changes in a cape-like distribution around the deltoid area with loss of pain and temperature sensation while sparing proprioception and vibration. This pattern is classically seen in syringomyelia, where a fluid-filled cavity (syrinx) in the cervical spinal cord damages the decussating fibers of the spinothalamic tract. Syringomyelia typically results from the formation of a syrinx in the central canal of the spinal cord, often associated with a Chiari I malformation but it may also follow trauma or be idiopathic. The expanding syrinx compresses the crossing fibers of the spinothalamic tract in the ventral white commissure, leading to bilateral loss of pain and temperature sensation in a 'cape-like' distribution while sparing the dorsal columns. The 'cape-like' distribution of diminished pinprick sensation along the shoulders and upper arms with preservation of proprioception is pathognomonic. Patients rarely have significant motor deficits in the early stages, and the lesion is typically localized to the cervical region. Differential diagnoses include cervical cord lesions due to other etiologies (e.g., multiple sclerosis, tumors) but the specific sensory pattern in syringomyelia is distinctive. MRI of the cervical spine is the diagnostic modality of choice, clearly demonstrating the syrinx. Initial management includes confirming the diagnosis with MRI. Surgical decompression is considered, especially when associated with Chiari malformation, to prevent progression. Physical therapy is used to manage symptoms. In pregnant or lactating patients, MRI is still generally safe (without contrast), and if surgery is indicated, timing and anesthetic management require multidisciplinary discussion to balance maternal and fetal risks. Option A (Syringomyelia) is correct. There are no other provided options, but differential considerations would include other cervical myelopathies which typically would not produce the classic cape distribution with preserved dorsal column function. \u2022 The 'cape-like' distribution of sensory loss with preserved vibration and proprioception is almost pathognomonic for syringomyelia. \u2022 Association with Chiari I malformation should always be considered. Recent guidelines emphasize the role of high-resolution MRI in diagnosing syringomyelia and support early neurosurgical consultation when symptomatic progression is noted. Advances in surgical techniques have improved outcomes, though careful monitoring remains key.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Typical scenario of HMSN. Biopsy shows onion bulb. What gene?",
    "option_a": "PMP 22 duplication",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "The scenario describes a patient with hereditary motor and sensory neuropathy (HMSN) where the muscle biopsy reveals an 'onion bulb' formation. This is most commonly seen in Charcot-Marie-Tooth disease type 1A (CMT1A), which is due to a duplication of the PMP22 gene. The duplication of the PMP22 gene on chromosome 17 leads to an abnormal production of peripheral myelin protein, resulting in a demyelinating neuropathy. The repeated cycles of demyelination and remyelination cause the proliferation of Schwann cells, which histologically appears as 'onion bulbs.' CMT1A typically presents with slowly progressive distal muscle weakness, atrophy (especially in the lower legs leading to foot drop), sensory loss, and high-arched feet (pes cavus). The condition is usually inherited in an autosomal dominant fashion, and a family history is common. Differential diagnoses include other hereditary neuropathies (such as CMT types 2, 4, or X-linked forms) and acquired demyelinating neuropathies like chronic inflammatory demyelinating polyneuropathy (CIDP). Electrophysiological studies, nerve conduction studies, and genetic testing are key in making an accurate diagnosis. There is no cure for CMT; management focuses on supportive care including physical therapy, orthotic devices, and occupational therapy. Regular follow-up is important to address complications such as foot deformities. In pregnancy and lactation, supportive and rehabilitative measures remain the mainstay of treatment, with a multidisciplinary team approach to ensure safety and optimize function. Option A (PMP22 duplication) is correct because it is the genetic defect most commonly associated with CMT1A, the prototype of hereditary motor and sensory neuropathy with onion bulb pathology. Other genetic mutations (such as MPZ or GJB1) cause different subtypes of CMT and are not as common as the PMP22 duplication in this context. \u2022 'Onion bulb' formations in nerve biopsies are indicative of chronic remyelination seen in CMT1A. \u2022 High-arched feet (pes cavus) and distal muscle wasting are common clinical findings. Recent guidelines emphasize genetic testing for accurate diagnosis of hereditary neuropathies. While no disease-modifying therapies exist, ongoing research in gene therapy may offer future treatments. Current management continues to be multidisciplinary and supportive.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Patient with myopathy affects mainly posterior leg compartment with CK 7000. DX?",
    "option_a": "Myoshi disease",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "This question describes a patient with a myopathy predominantly affecting the posterior compartment of the leg, accompanied by a significantly elevated creatine kinase (CK) level of 7000. This clinical picture is consistent with Miyoshi myopathy (also known as Myoshi myopathy), a distal muscular dystrophy that primarily involves the calf muscles. Miyoshi myopathy is caused by mutations in the dysferlin gene, which encodes a protein critical for muscle membrane repair. The defective protein leads to muscle fiber degeneration and regeneration, resulting in high serum CK levels and the characteristic pattern of muscle weakness, particularly in the posterior compartment of the legs. Patients typically present in young adulthood with difficulty in activities such as running or toe walking due to early involvement of the gastrocnemius and soleus muscles. The markedly elevated CK level reflects ongoing muscle degeneration. The pattern of weakness (posterior compartment predominance) helps distinguish it from other myopathies. The differential diagnosis includes other distal myopathies such as distal limb-girdle muscular dystrophies and inclusion body myositis (which tends to occur in older individuals with a different distribution of weakness). Electromyography, muscle biopsy, and most importantly, genetic testing for dysferlin mutations are key diagnostic tools. Currently, there is no cure for Miyoshi myopathy. Management is supportive and includes physical therapy, occupational therapy, and assistive devices to improve mobility. Regular monitoring and management of complications are essential. In pregnancy and lactation, management remains supportive; physical therapy and appropriate safety measures are recommended, while avoidance of medications that may exacerbate muscle damage is important. Multidisciplinary care is crucial. Option A (Myoshi disease) is correct as it accurately describes a distal myopathy that predominantly affects the posterior compartment of the leg with markedly elevated CK levels. Other options might include various other myopathies or muscular dystrophies, but none fit the classic presentation and lab findings as well as Miyoshi myopathy. \u2022 Miyoshi myopathy typically presents with early calf weakness and elevated CK levels, often in the thousands. \u2022 Genetic testing for dysferlin mutations is key in confirming the diagnosis. Recent research has focused on understanding dysferlin\u2019s role in muscle repair and exploring potential gene therapy approaches. Current guidelines emphasize supportive care and regular multidisciplinary evaluations to maintain function and quality of life in affected patients.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Long scenario, elderly, peripheral neuropathy, organomegaly, \u2191 M protein and limbs edema - which test to send? (typical POEMS)",
    "option_a": "anti MAG",
    "option_b": "VEGF",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "POEMS syndrome is a rare multisystem disorder associated with an underlying plasma cell dyscrasia. The acronym stands for Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein, and Skin changes. Recognizing the constellation of these findings is key to suspecting this syndrome. The syndrome is driven by an overproduction of cytokines, in particular vascular endothelial growth factor (VEGF). Elevated VEGF leads to increased vascular permeability, edema, and contributes to organomegaly. The plasma cell dyscrasia produces a monoclonal M-protein which is part of the syndrome\u2019s definition. An elderly patient presenting with a demyelinating peripheral neuropathy, organomegaly (e.g., hepatosplenomegaly), monoclonal protein (M protein), and limb edema is highly suggestive of POEMS syndrome. The elevated VEGF levels directly correlate with disease activity and severity. Diagnosis relies on clinical criteria supported by laboratory tests. Key tests include serum VEGF level measurement, nerve conduction studies demonstrating demyelinating features, and further evaluations such as bone marrow biopsy to assess plasma cell dyscrasia. Differential diagnoses include multiple myeloma and other monoclonal gammopathies, but the specific constellation of organomegaly, edema, and neuropathy helps differentiate POEMS. First-line therapies may include localized radiotherapy (if a solitary plasmacytoma is identified) or systemic therapies such as corticosteroids, alkylating agents (e.g., melphalan), immunomodulatory drugs (lenalidomide/thalidomide), and autologous stem cell transplantation in eligible patients. Supportive management for neuropathic symptoms is important. In pregnancy and lactation, caution is required with chemotherapeutic agents; treatment decisions should balance maternal benefits and fetal risks, and alternatives like IVIG may be considered if appropriate. Option A (anti-MAG) is used in the evaluation of certain demyelinating neuropathies (e.g., anti-MAG neuropathy) but does not correlate with the systemic features seen in POEMS. Option B (VEGF) is the appropriate test since elevated serum VEGF is a hallmark of POEMS syndrome. Options C and D are not provided. 1. Elevated VEGF is almost pathognomonic for POEMS syndrome when seen in the appropriate clinical setting. 2. The unique combination of neuropathy with organomegaly and M protein should always prompt consideration of POEMS. Recent studies have underscored the importance of VEGF levels in both the diagnosis and monitoring of POEMS syndrome. Contemporary guidelines stress the use of VEGF as a sensitive and specific biomarker, guiding both diagnosis and therapeutic response.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "40 years old male with proximal upper and lower limbs weakness associated with tremors and tongue atrophy and fasciculation. Labs revealed \u2191 androgen levels. What else associated?\nN.B: typical scenario of Kennedy disease.",
    "option_a": "Diabetes mellitus.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "Kennedy disease, also known as spinal and bulbar muscular atrophy (SBMA), is an X-linked neuromuscular disorder characterized by slowly progressive muscle weakness and atrophy, as well as distinctive endocrine abnormalities. The disease is caused by an expanded CAG trinucleotide repeat in the androgen receptor gene. This leads to a mutant androgen receptor that both accumulates in motor neurons, causing neuronal degeneration, and alters androgen signaling. The resultant partial androgen insensitivity is the reason for endocrine manifestations such as gynecomastia. A 40-year-old male presenting with proximal weakness in both upper and lower limbs, tremors, tongue atrophy, and fasciculations is typical for Kennedy disease. The laboratory finding of increased androgen levels coexists with clinical signs of androgen insensitivity, such as gynecomastia, which is the classic associated feature. The diagnosis is confirmed by genetic testing demonstrating an expanded CAG repeat in the androgen receptor gene. The differential diagnosis includes motor neuron diseases such as ALS; however, ALS lacks the endocrine abnormalities and sensory involvement seen in Kennedy disease. There is no curative treatment. Management is mainly supportive with physical therapy and symptomatic care. Endocrine symptoms (like gynecomastia) may be managed conservatively. Since the condition primarily affects males, pregnancy and lactation considerations are not directly applicable; however, genetic counseling is important for family planning purposes. Option A (Diabetes mellitus) is not typically associated with Kennedy disease. Option B, which corresponds to gynecomastia, correctly highlights the endocrine dysfunction seen in this condition and is therefore the appropriate answer. Other options are either not relevant or not commonly associated with Kennedy disease. 1. Kennedy disease presents with both motor neuron signs and endocrine abnormalities such as gynecomastia and testicular atrophy. 2. Genetic testing is definitive, highlighting the importance of family history and appropriate counseling. Recent research continues to support the central role of androgen receptor gene testing in diagnosing Kennedy disease. Emphasis remains on supportive care and symptomatic management, with ongoing studies exploring potential targeted therapies.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Elderly female with typical features of CIDP (DADS variant), and picture of significant demyelinating neuropathy. Which antibody to test?",
    "option_a": "MAG antibodies",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is an immune-mediated neuropathy. The DADS (Distal Acquired Demyelinating Symmetric) variant is a form of CIDP that often presents in older patients with predominantly distal symptoms. In the DADS variant, demyelination is typically localized to distal nerve segments. Many patients have an underlying IgM monoclonal gammopathy with antibodies directed against myelin-associated glycoprotein (MAG), which mediate immune attack on peripheral nerve myelin. Elderly patients with a predominantly distal neuropathy, sensory ataxia, and sometimes tremor are typical of the DADS variant. The presence of significant demyelinating features on nerve conduction studies along with these clinical findings strongly suggests an anti-MAG associated neuropathy. The workup includes nerve conduction studies demonstrating demyelination, serologic evaluation for monoclonal gammopathies, and testing for anti-MAG antibodies. Differential diagnoses include other variants of CIDP and hereditary demyelinating neuropathies; the identification of anti-MAG antibodies helps distinguish DADS from these conditions. First-line treatment often includes immunomodulatory therapies such as IVIG or corticosteroids. Plasmapheresis may be used as a second-line option, and rituximab has shown promise specifically in anti-MAG neuropathy. For elderly patients, treatment selection must account for comorbidities; if a woman of childbearing potential were affected, IVIG would be preferred during pregnancy due to its favorable safety profile. Option A (MAG antibodies) is correct because the DADS variant of CIDP is closely linked with the presence of anti-MAG antibodies. This serologic marker helps confirm the diagnosis and differentiate it from other neuropathies. Other options are either not relevant or less specific. 1. The presence of an IgM monoclonal gammopathy with anti-MAG antibodies is a key finding in the DADS variant of CIDP. 2. Distal demyelinating features with sensory involvement should prompt consideration of this variant. Current guidelines and recent studies emphasize antibody testing (especially anti-MAG) in patients with suspected DADS, thereby guiding tailored immunomodulatory therapy. Newer agents like rituximab are increasingly being used in refractory cases.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Patient with picture of Mitochondrial disease; sensory motor demyelinating neuropathy, nausea, vomiting, and GIT symptoms. What test is crucial? (Looks like MNGIE disease)",
    "option_a": "Pyruvate/Lactate",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE) is a rare, multisystem mitochondrial disorder characterized by a combination of gastrointestinal dysmotility, peripheral neuropathy, and central nervous system involvement. MNGIE is caused by mutations in the TYMP gene which result in a deficiency of thymidine phosphorylase. This enzyme deficiency leads to the accumulation of thymidine and deoxyuridine, causing imbalances in the mitochondrial nucleotide pool. The subsequent mitochondrial DNA damage results in the systemic manifestations of the disease. Patients typically present with gastrointestinal symptoms (nausea, vomiting, abdominal pain, and weight loss) accompanied by a sensory-motor demyelinating neuropathy. The combination of prominent gastrointestinal dysmotility with neurologic deficits is a clinical hallmark of MNGIE. The crucial diagnostic test in MNGIE is the measurement of thymidine phosphorylase activity and/or the detection of elevated plasma levels of thymidine and deoxyuridine. While pyruvate/lactate measurements are useful in other mitochondrial disorders (e.g., MELAS), they are not definitive for MNGIE. Differential diagnoses include other mitochondrial cytopathies and gastrointestinal motility disorders, but the specific biochemical abnormalities distinguish MNGIE. Management is primarily supportive, focusing on nutritional support, symptomatic relief for gastrointestinal dysmotility, and physical therapy for neuropathic symptoms. Investigational treatments include allogeneic hematopoietic stem cell transplantation, enzyme replacement, and gene therapy. In the context of pregnancy, therapeutic options are limited due to potential teratogenicity; thus, management should be multidisciplinary with an emphasis on supportive care and careful risk\u2013benefit assessment. Option A (Pyruvate/Lactate) is typically used to evaluate other mitochondrial disorders but is not the key test for diagnosing MNGIE. Option B, which likely represents the assessment of thymidine phosphorylase activity (or measurement of plasma thymidine and deoxyuridine levels), is the crucial test in confirming the diagnosis of MNGIE. Therefore, the marked answer B is correct. 1. A deficiency in thymidine phosphorylase leading to accumulation of thymidine is pathognomonic for MNGIE. 2. The combination of severe gastrointestinal dysmotility with a demyelinating neuropathy should raise suspicion for this mitochondrial disorder. Recent studies have reinforced the utility of plasma nucleoside measurement and enzyme assay in diagnosing MNGIE. Experimental therapies, including stem cell transplantation, are under investigation and represent potential future treatment avenues.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Elderly with sensory and autonomic neuropathy, bilateral CTS and family history of restricted cardiomyopathy. Dx?",
    "option_a": "Transtheritic amyloidosis",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Hereditary transthyretin amyloidosis is an inherited disorder wherein misfolded transthyretin proteins deposit as amyloid fibrils in multiple tissues, including peripheral nerves and the heart. The clinical picture of sensory and autonomic neuropathy, bilateral carpal tunnel syndrome, and familial cardiomyopathy points toward an amyloid deposition process mediated by mutant transthyretin. Mutations in the TTR gene destabilize the normally tetrameric transthyretin protein, leading to dissociation into misfolded monomers. These misfolded proteins aggregate forming amyloid fibrils that deposit in tissues such as peripheral nerves, the carpal tunnel region, and the myocardium. The deposition causes nerve damage (resulting in sensory and autonomic neuropathy) and restrictive cardiomyopathy due to stiff, infiltrated cardiac muscle. Patients often present in later life with a combination of peripheral neuropathy (manifesting as sensory deficits and dysautonomia), carpal tunnel syndrome (often bilateral), and a familial history of cardiomyopathy. The restricted (or restrictive) cardiomyopathy seen in affected relatives reinforces the suspicion of a systemic amyloid process. Key differentials include wild\u2010type (senile) amyloidosis, diabetic neuropathy, and other hereditary neuropathies. Diagnostic workup typically involves cardiac imaging (echocardiography, MRI) for cardiomyopathy features, nerve conduction studies for neuropathy, and tissue biopsy (e.g., abdominal fat pad or nerve biopsy) with Congo red staining. Genetic testing for TTR mutations confirms the diagnosis and helps differentiate from wild\u2010type amyloidosis. First-line treatment for hereditary ATTR amyloidosis includes transthyretin stabilizers such as tafamidis, which slow disease progression. Recently approved gene-silencing therapies (patisiran, inotersen) target TTR production. Management must be multidisciplinary, including cardiology and neurology care, as well as genetic counselling. In pregnant or lactating patients, data is limited so treatment decisions require a careful risk-benefit analysis with consideration of available safety profiles and potential teratogenic effects. Option A, transthyretin amyloidosis, is correct because it most specifically links the constellation of neuropathy, bilateral CTS, and familial restrictive cardiomyopathy. Other options, though not explicitly listed here, would likely include other forms of systemic amyloidosis or neuropathies which do not account for the familial cardiomyopathy aspect. 1. Bilateral carpal tunnel syndrome can be an early red flag for amyloid deposition. 2. A family history of restrictive cardiomyopathy in the context of neuropathy should prompt consideration of hereditary ATTR amyloidosis. 3. Confirmation requires a combination of histologic, genetic, and cardiac evaluation. Latest research emphasizes early intervention with tafamidis and the emerging role of gene-silencing agents in altering disease progression. Updated guidelines advocate for prompt genetic testing and multidisciplinary management for optimal outcomes.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Commonest cause of myopathy in elderly > 50 years of age?",
    "option_a": "IBM.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Inclusion Body Myositis (IBM) is recognized as the most common acquired myopathy in patients older than 50 years. It is a distinct inflammatory myopathy that predominantly affects the elderly with a characteristic pattern of muscle weakness. IBM is characterized by both inflammatory and degenerative processes. It involves an immune-mediated component with endomysial inflammatory infiltrates and the presence of rimmed vacuoles on muscle biopsy. Misfolded protein aggregates, including \u03b2-amyloid and other proteins, contribute to myofiber degeneration. Clinically, IBM presents with slowly progressive and often asymmetrical weakness, notably in the distal muscles (especially finger flexors) and proximal muscles (such as the quadriceps). It may also feature dysphagia. Importantly, IBM is typically resistant to corticosteroids and other immunosuppressive therapies, distinguishing it from other inflammatory myopathies. Differential diagnoses include polymyositis, dermatomyositis, and steroid-induced myopathy. Muscle biopsy showing rimmed vacuoles and endomysial inflammation is diagnostic. Serum creatine kinase levels may be mildly elevated, and electromyography demonstrates mixed neurogenic and myopathic changes. Autoantibody panels help exclude other inflammatory myopathies. Currently, there is no proven effective immunosuppressive therapy for IBM. The mainstay of management is supportive care, including physical therapy and occupational therapy to maintain function. Investigational treatments are under study but none have yet become standard of care. Regarding pregnancy or lactation, given the age group (typically >50), these are rarely applicable; however, any potential therapeutic interventions should consider safety profiles if used in women of childbearing potential. Option A (IBM) is the correct answer because it is widely recognized as the most common cause of myopathy in patients over 50. Other potential causes \u2013 such as polymyositis \u2013 are less common in this age group and have different clinical and histological features. 1. IBM is often refractory to immunomodulatory treatment. 2. Characteristic muscle biopsy findings (rimmed vacuoles) are essential for diagnosis. 3. Finger flexor and quadriceps weakness should prompt consideration of IBM in older patients with myopathy. Recent studies support the non-inflammatory degenerative component of IBM, with ongoing trials investigating novel therapeutic agents targeting protein misfolding. Current guidelines emphasize rehabilitation and supportive management over immunosuppressive treatment.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Typical scenario of Myasthenia Gravis in young lady with fluctuating ptosis - what is the best sensitive test in her case?",
    "option_a": "Single fiber EMG.",
    "option_b": "Ach receptor antibodies.",
    "option_c": "Antismiched muscle abs.",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Myasthenia Gravis (MG) is an autoimmune disorder characterized by antibodies that impair neuromuscular transmission, typically through attack on acetylcholine receptors. Accurate and sensitive testing is critical, especially in cases with ocular manifestations like fluctuating ptosis. MG involves autoantibodies\u2014most commonly against acetylcholine receptors\u2014that lead to receptor internalization and complement-mediated damage at the neuromuscular junction. This results in impaired neuromuscular transmission and muscle fatigue. In some patients, antibodies against muscle-specific kinase (MuSK) or other related proteins may be present. The hallmark of MG is fluctuating muscle weakness that worsens with activity and improves with rest. Ocular involvement, presenting as ptosis and diplopia, is common, particularly in young women. The variability and distribution of muscle weakness make clinical diagnosis challenging without supportive diagnostic tests. Diagnostic evaluation begins with clinical assessment and may include acetylcholine receptor antibody testing, which is highly specific but has lower sensitivity in ocular MG. The repetitive nerve stimulation test can also be used. However, the single fiber electromyography (SFEMG) test is the most sensitive, detecting neuromuscular transmission variability even in early or seronegative MG. First-line symptomatic treatment includes acetylcholinesterase inhibitors such as pyridostigmine. Immunomodulatory therapies (e.g., corticosteroids, azathioprine) and thymectomy may be indicated in generalized cases. In pregnancy, pyridostigmine is considered safe; however, immunosuppressants require careful consideration given potential fetal hazards and lactation guidelines. Option A (Single fiber EMG) is correct because of its superior sensitivity in detecting abnormal neuromuscular transmission in MG, particularly in cases with solely ocular involvement where antibody levels might be low. Option B (Ach receptor antibodies) is specific but less sensitive especially in ocular MG, and Option C (Antismiched muscle abs) is not a standard diagnostic test in MG. 1. Single fiber EMG is the most sensitive diagnostic tool for MG. 2. Ocular MG can have negative antibody tests, making electrophysiological studies essential. 3. Fluctuating muscle weakness that worsens with activity is the clinical hallmark of MG. Recent guidelines continue to support the use of SFEMG as the gold standard for sensitivity in diagnosing MG. Moreover, updated research reinforces tailored management strategies based on antibody profiles and clinical presentation, enhancing patient outcomes.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "54 years old male has progressive asymmetrical weakness started in right leg then ascends to both arms, with no sensory, ocular or autonomic features. On examination there is brisk DTR with atrophy and fasciculation. Very typical scenario of ALS - What is the Dx?",
    "option_a": "ALS.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder involving both the upper and lower motor neurons. It is characterized by a specific pattern of muscle weakness that is not accompanied by sensory, ocular, or autonomic involvement. The disease process in ALS involves degeneration of motor neurons in the primary motor cortex, brainstem, and spinal cord. This leads to a combination of upper motor neuron signs (such as brisk deep tendon reflexes) and lower motor neuron signs (such as muscle atrophy, fasciculations, and weakness). The precise etiology is multifactorial, involving genetic and environmental factors. Patients typically present with asymmetrical, progressive limb weakness that starts focally and then spreads. The absence of sensory deficits and the presence of both upper motor neuron (spasticity, brisk reflexes) and lower motor neuron (atrophy, fasciculations) findings are highly suggestive of ALS. The description provided precisely mirrors these clinical features. The diagnosis of ALS is primarily clinical, supported by electrophysiological studies (electromyography) that demonstrate widespread denervation and reinnervation changes. Differential diagnoses include multifocal motor neuropathy, cervical spondylotic myelopathy, and other motor neuron diseases. No specific biomarker is available; hence, the revised El Escorial criteria for ALS diagnosis is commonly used. The only FDA-approved disease-modifying treatments for ALS are riluzole and edaravone. Riluzole can modestly prolong survival and delay respiratory decline, while edaravone has been shown to slow functional deterioration in selected patients. Management is supportive and includes multidisciplinary care with physical therapy, respiratory support, and nutritional management. Pregnancy considerations in ALS are rare due to the typical age of onset, but any use of disease-modifying therapies during pregnancy or lactation requires careful risk-benefit evaluation due to limited data. Option A (ALS) is correct given the description of progressive, asymmetrical weakness with both upper and lower motor neuron signs and a lack of sensory or autonomic involvement. Other options (if provided) would likely consider conditions with either sensory deficits or different patterns of weakness, which are inconsistent with the typical presentation of ALS. 1. ALS classically presents with a mixture of upper and lower motor neuron signs. 2. The absence of sensory deficits is a key distinguishing feature. 3. Early multidisciplinary management is essential to improve quality of life. Recent advances focus on genetic research and novel therapeutic targets, with ongoing trials examining potential neuroprotective agents. Current clinical guidelines still prioritize riluzole and multidisciplinary supportive care as the mainstays of ALS management.",
    "exam_year": "2022",
    "exam_type": "Part I"
  }
]